Medical Health & Life Science Research News

Research details developments in the dermatology drugs global market forecast to 2023

Research details developments in the dermatology drugs global market forecast to 2023

A new research document with title 'Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis' covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions and important players/vendors. The report will help user gain market insights, future trends and growth prospects for forecast period of 2017-2023

- Advertisement -
- Membership expired -

Summary
Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 types of dermatological conditions are thought to exist, ranging from the autoimmune disorder psoriasis to the very common condition acne vulgaris. The scope of dermatological disorders is diverse in terms of severity and clinical presentation, and if a condition is not sufficiently kept under control, it can significantly impair the patient’s quality of life.

Request a sample report @ www.htfmarketreport.com/sample-rep…logy-drugs-market 

The treatment landscape for dermatological disorders was traditionally dominated by genericized topical therapies such as glucocorticoids and retinoids.

- Advertisement -
- Membership expired -
The approval of monoclonal antibodies (mAbs) such as Humira, Enbrel and Remicade for psoriasis revolutionized both the management of psoriasis and the dermatology therapy area. These first generation mAbs are now off-patent and have biosimilar versions approved by the FDA, but in recent years the therapy area has seen a number of new mAbs enter the market. These new approvals will provide patients with more treatment options and stimulate growth in the therapy area. In 2017 Dupixent became the first biologic to be approved for atopic dermatitis, expanding the use of biologics to an indication other than psoriasis.

Overall there are 871 products being actively developed in the dermatology pipeline, but these include products being developed for many smaller indications. The indications with the largest pipelines are psoriasis, atopic dermatitis and acne vulgaris, which contain 282, 136 and 70 products, respectively.

Scope

- Global revenue from the dermatology market is forecast to increase from $19.8 billion in 2016 to $36.6 billion in 2023, at a compound annual growth rate of 9.13%. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- What are the leading companies in terms of market share?
- Which companies are forecast to experience the largest growth in market share?
- Which companies rely heavily on revenue derived from antibacterial drugs?
- How will the market respond to recent approvals?
- Will generics and biosimilars have a significant impact on the market over the forecast period?
- What class of drugs dominate the market?
- What molecular targets are most popular in the pipeline?
- What are the commercial prospects for the most promising late-stage products?

Reasons to access


- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the dermatology pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- This review also provides a detailed look at dermatology product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.
- Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals.


Get report @ www.htfmarketreport.com/request-di…logy-drugs-market

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 10
2.1 Therapy Area Introduction 10
2.2 Symptoms 10
2.3 Etiology and Pathophysiology 11
2.3.1 Atopic Dermatitis 11
2.3.2 Acne Vulgaris 13
2.3.3 Psoriasis 14
2.4 Co-morbidities and Complications 14
2.5 Diagnosis, Scales and Grading 15
2.5.1 Atopic Dermatitis 15
2.5.2 Acne Vulgaris 16
2.5.3 Psoriasis 17
2.6 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation 17
2.6.1 Atopic Dermatitis 18
2.6.2 Acne Vulgaris 19
2.6.3 Psoriasis 20
2.7 Treatment 21
2.7.1 Topical Corticosteroids 22
2.7.2 Calcineurin Inhibitors 23
2.7.3 Retinoids 23
2.7.4 Systemic Immunosuppressive Agents 24
2.7.5 Biologics 25
2.7.6 Antihistamines 25
2.7.7 Hormonal Therapy 26
2.7.8 Moisturizers 26
3 Key Marketed Products 27
3.1 Overview 27
3.2 Humira (adalimumab) - AbbVie 27
3.3 Remicade (infliximab) - Johnson & Johnson 29
3.4 Enbrel (etanercept) - Amgen 31
3.5 Stelara (ustekinumab) - Johnson & Johnson 33
3.6 Neoral (cyclosporine) - Novartis 34
3.7 Protopic (tacrolimus) - Astellas Pharma 36
3.8 Cosentyx (Secukinumab) - Novartis 37
3.9 Dupixent (dupilumab) Sanofi and Regeneron 39
3.10 Taltz (ixekizumab) - Eli Lilly 41
3.11 Eucrisa (crisaborole) - Pfizer 43
3.12 Siliq (Brodalumab) - Valeant Pharmaceuticals 44
3.13 Elidel (pimecrolimus) 46
3.14 Elocon (mometasone furoate) 46
3.15 Differin (adapalene) 47
3.16 Metolate (methotrexate) 48
3.17 Clobex (clobetasol propionate) 48
3.18 Conclusion 49
4 Pipeline Landscape Assessment 50
4.1 Overview 50
4.2 Molecule Types in the Pipeline 53
4.3 Molecular Targets in the Pipeline 54
4.4 Clinical Trials 56
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 57
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 61
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 65
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 69
4.4.5 Assessment of Key Pipeline Products 72
4.5 Conclusion 78
5 Multi-scenario Market Forecast to 2023 79
5.1 Overall Market Size 79
5.2 Generic Penetration 81
5.3 Revenue Forecast by Molecular Target 82
5.3.1 Tumor Necrosis Factor-Alpha 82
5.3.2 Interleukins 1, 4, 5, 12, 17 and 23 and Receptors 83
5.3.3 Calcineurin 85
5.3.4 Glucocorticoid Receptors 86
5.3.5 Phosphodiesterase 4 87
6 Company Analysis and Positioning 88
6.1 Revenue and Market Share Analysis by Company 89
6.1.1 No

....Continued

View Detailed Table of Content @ www.htfmarketreport.com/reports/63…logy-drugs-market


Access this report @ www.htfmarketreport.com/buy-now?fo…amp;report=633872

News From

HTF Market Intelligence ConsultingHTF Market Intelligence...
Category: Market Research Publishers and RetailersCompany profile: HTF Market Report is wholly owned brand of HTF market Intelligence Consulting Private Limited which provides next-generation service for organizations with a deep focus on market intelligence, data analytics, and social intelligence, all uniquely delivered under one roof by skilled professionals. By combining and analyzing acquire lucid and most relevant data which would help in better decision-making. We provide your requirements with speed and cost benefit across the world, we are able to achi ...

For more information:

Make an Inquiry about this report HERE!
  • www.htfmarketreport.com
  • www.htfmarketreport.com/sample-rep…logy-drugs-market
  • www.htfmarketreport.com/request-di…logy-drugs-market
  • www.htfmarketreport.com/reports/63…logy-drugs-market
  • www.htfmarketreport.com/buy-now?fo…amp;report=633872